Results 81 to 90 of about 14,299,063 (394)
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]
, 2000 Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston +2 more
core
Severe Hemophilia A in a Male Old English Sheep Dog with a C→T Transition that Created a Premature Stop Codon in Factor VIII [PDF]
, 2016 Animals with hemophilia are models for gene therapy, factor replacement, and inhibitor development in humans. We have actively sought dogs with severe hemophilia A that have novel factor VIII mutations unlike the previously described factor VIII intron ...
Bellinger, Dwight +7 more
core +2 more sources
Journal of Thrombosis and Haemostasis, 2014 BAY 94‐9027 is a B‐domain‐deleted recombinant factor VIII (rFVIII) with site‐specific attachment of poly(ethylene glycol) that has shown an extended half‐life in animal models of hemophilia.
T. Coyle +9 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam +2 more
wiley +1 more source
Recurrent Cerebral Venous Thrombosis Associated with Elevated Factor VIII [PDF]
, 2006 Cerebral venous thrombosis (CVT) rarely recurs, and the factors associated with a recurrence remain unclear. Recently, however, elevated plasma coagulation factor VIII has been considered a factor related to recurrent venous thromboembolism.
A-Hyun Cho +18 more
core +2 more sources
Clinical and Laboratory Approaches to Hemophilia A
Iranian Journal of Medical Sciences, 2015 Hemophilia A is a worldwide disorder of coagulation system. It is a male disorder, yet females with hemophilia are rarely seen in communities with high rate of consanguineous marriages.
Hassan Mansouritorghabeh
doaj
In Vitro Modeling of the Influence of FVIII Activity and Heparin Induced Prolongation of APTT
Biomolecules & Biomedicine, 2008 Anticoagulant therapy is most commonly assessed by measuring the effect of the drug on global clotting assay, such as APTT. It is known that response of the APTT to hepa-rin may be decreased in patients with high levels of factor VIII.
Aida Mehmedagić +3 more
doaj +1 more source
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer
Molecular Oncology, EarlyView.This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu +7 more
wiley +1 more source
Orphanet Journal of Rare Diseases, 2023 Background Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which leads to severe and repeated bleedings. There is a need to understand the optimal treatment pathway for FVIII inhibitors with the use of immune ...
George Morgan +4 more
doaj +1 more source